Problems of rituximab as the targeting therapy for non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2008.04.029
- VernacularTitle:利妥昔单抗靶向治疗非霍奇金淋巴瘤中存在的问题
- Author:
Yiwen ZHANG
;
Weili ZHAO
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Targeted therapy
- From:
Journal of Leukemia & Lymphoma
2008;17(4):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Ten years had passed for the molecular targeted therapy since approval by the U.S.Food and Drug Administration of the first monoclonal antibody-Rituximab,for the treatment of the B-cell non-Hodgkin's lymphomas with positive CD20- The targeting therapy,which may be a promising approach in the future,has significantly improved the patients'qualities of lives and prognosis because it has higher selectivity and less adverse effects than current chemotherapy and radiotherapy.In the past decade,with the fast development of novel targeting drugs and extension of therapeutic fields,the limitations associated with the targeted treatments were received attentions.
